CCR Clinical Trials at NIH: Clinical Research: Search for Clinical Trials at NIH

The NCI Center for Cancer Research (CCR) conducts more than 150 cancer clinical trials at the National Institutes of Health (NIH) Clinical Center in Bethesda, Maryland. Cancer clinical trials that take place at the NIH Clinical Center are open to patients with cancer, regardless of where they live in the United States.

Go to Search Page

There are 50 clinical trials at NIH that match your search criteria

Cancer by type/disease: Solid Tumor

Trial and Protocol Number Solid Tumor	Principal Investigator	Referral Contact
Phase II
Pilot Study of GRN1005 for Resectable Brain Metastases in Patients With Breast Cancer and Non-Small Cell Lung Cancer NCI-12-C-0199, NCT01679743	Susan Bates 301-402-5958	Christine Bryla 301-451-7868 brylacm@mail.nih.gov
A Phase II Study of Lymphodepletion Followed by Autologous Tumor-Infiltrating Lymphocytes and High-Dose Aldesleukin for Human Papillomavirus-Associated Cancers NCI-12-C-0116, NCT01585428	Steven A. Rosenberg 1-866-820-4505 (Toll Free)	June A. Kryk 1-866-820-4505 (Toll Free) ncisbirc@mail.nih.gov
A Phase II Study of Enhancement of Immune Reconstitution and Vaccine Responses With Administration of Glyco-Recombinant Human IL-7 in Older Subjects Following Chemotherapy NCI-11-C-0146, NCT01339000	Claude Sportès 301-435-5280	Zetta Blacklock 301-594-2056 bblacklock@mail.nih.gov
A Phase II Study Using Short-Term Cultured, CD8+-enriched Autologous Tumor-Infiltrating Lymphocytes Following a Lymphocyte Depleting Regimen in Metastatic Digestive Tract Cancers NCI-10-C-0166, NCT01174121	Steven A. Rosenberg 1-866-820-4505 (Toll Free)	June A. Kryk 1-866-820-4505 (Toll Free) ncisbirc@mail.nih.gov
A Multi-Histology Phase II Study of 5-Fluoro-2-Deoxycytidine With Tetrahydrouridine (FdCyd + THU) NCI-09-C-0214, NCT00978250	James H. Doroshow 301-496-4291	Janelle Bingham 301-435-2715 jbingham@mail.nih.gov
Phase II Study of Metastatic Cancer That Expresses NY-ESO-1 Using Lymphodepleting Conditioning Followed by Infusion of Anti-NY ESO-1 TCR-Gene Engineered Lymphocytes NCI-08-C-0121, NCT00670748	Steven A. Rosenberg 1-866-820-4505 (Toll Free)	June A. Kryk 1-866-820-4505 (Toll Free) ncisbirc@mail.nih.gov
Phase I/II
A Phase I/II Trial of IL-13-PE in Patients with Treatment Refractory Malignancies With a Focus on Metastatic and Locally Advanced Adrenocortical Carcinoma NCI-13-C-0046, NCT01766635	Electron Kebebew 301-496-5049	Erinn M. Hopkins 301-496-6457 erinn.hopkins@nih.gov
Phase I/II Study of Metastatic Cancer Using Lymphodepleting Conditioning Followed by Infusion of Anti-mesothelin Gene Engineered Lymphocytes NCI-12-C-0111, NCT01583686	Steven A. Rosenberg 1-866-820-4505 (Toll Free)	June A. Kryk 1-866-820-4505 (Toll Free) ncisbirc@mail.nih.gov
A Phase I/II Trial of Crolibulin (EPC2407) Plus Cisplatin in Adults With Solid Tumors With a Focus on Anaplastic Thyroid Cancer (ATC) NCI-11-C-0027, NCT01240590	Ann W. Gramza 301-827-4989	Erinn M. Hopkins 301-496-6457 erinn.hopkins@nih.gov
Phase I/II Study of Metastatic Cancer Using Lymphodepleting Conditioning Followed by Infusion of Anti-VEGFR2 Gene Engineered CD8+ Lymphocytes NCI-11-C-0013, NCT01218867	Steven A. Rosenberg 1-866-820-4505 (Toll Free)	June A. Kryk 1-866-820-4505 (Toll Free) ncisbirc@mail.nih.gov
Phase I
A Phase I, Open-label, Multiple-Ascending Dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of MSB0010718C, a Monoclonal Anti-PD-L1 Antibody, in Adults With Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications NCI-13-C-0063, NCT01772004	James L. Gulley 301-435-2956	Laura D. Otten 301-451-1228 1-866-611-6310 (Toll Free) ottenl@mail.nih.gov
A Phase I Study of Single-agent MK-1775, a Wee1 Inhibitor, in Patients With Advanced Refractory Solid Tumors NCI-13-C-0032, NCT01748825	Shivaani Kummar 301-435-0517	Janelle Bingham 301-435-2715 jbingham@mail.nih.gov
A Phase I Study of an Adenoviral Transduced Autologous Dendritic Cell Vaccine Expressing Human HER2/neu ECTM in Adults With Tumors With 1-3+ HER2/neu Expression NCI-13-C-0016, NCT01730118	Lauren V. Wood 301-402-0199	Brenda Roberson 301-435-4733 broberson@mail.nih.gov
A Phase I and Pharmacokinetic Single-agent Study of Romidepsin in Patients With Lymphomas, Chronic Lymphocytic Leukemia, Select Solid Tumors, and Varying Degrees of Liver Dysfunction NCI-12-C-0177, NCT01638533	Shivaani Kummar 301-435-0517	Janelle Bingham 301-435-2715 jbingham@mail.nih.gov
A Phase I Study of a Continuous Intravenous Infusion of Recombinant Human Interleukin IL-15 (rhIL-15) in Adults With Metastatic Cancers NCI-12-C-0113, NCT01572493	Kevin Conlon 301-496-7417	Tat’Yana Worthy 301-496-0499 worthyt@mail.nih.gov
Phase I Trial of Oral 5-Fluoro-2-Deoxycytidine With Oral Tetrahydrouridine in Patients With Advanced Solid Tumors NCI-12-C-0066, NCT01534598	James H. Doroshow 301-496-4291	Janelle Bingham 301-435-2715 jbingham@mail.nih.gov
An Open Label Phase I Study to Evaluate the Safety and Tolerability of GI-6301 Vaccine Consisting of Whole, Heat-killed Recombinant Saccharomyces Cerevisiae (Yeast) Genetically Modified to Express Brachyury Protein in Adults With Solid Tumors NCI-12-C-0056, NCT01519817	James L. Gulley 301-435-2956	Laura D. Otten 301-451-1228 1-866-611-6310 (Toll Free) ottenl@mail.nih.gov
Phase Ib Study of the Combination of Pazopanib, an Oral VEGFR Inhibitor, and ARQ 197 (Tivantinib), an Oral MET Inhibitor, in Patients With Refractory Advanced Solid Tumors NCI-12-C-0009, NCT01468922	Shivaani Kummar 301-435-0517	Janelle Bingham 301-435-2715 jbingham@mail.nih.gov
An Open Label Phase I Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Maximum Tolerated Dose of the Anti-mesothelin Antibody Drug Conjugate BAY94-9343 in Subjects With Advanced Solid Tumors NCI-12-C-0008, NCT01439152	Raffit Hassan 301-451-8742	Yvonne Mallory 301-402-0255 malloryy@mail.nih.gov
Phase I Trial of NHS-IL12 in Subjects With Metastatic Solid Tumors NCI-11-C-0225, NCT01417546	James L. Gulley 301-435-2956	Laura D. Otten 301-451-1228 1-866-611-6310 (Toll Free) ottenl@mail.nih.gov
A Phase I Study of the Hsp90 Inhibitor, PU-H71, in Patients With Refractory Solid Tumors and Low-Grade Non-Hodgkin’s Lymphoma NCI-11-C-0150, NCT01581541	Shivaani Kummar 301-435-0517	Janelle Bingham 301-435-2715 jbingham@mail.nih.gov
Phase I Trial of Z-Endoxifen in Adults With Refractory Hormone Receptor-Positive Breast Cancer, Desmoid Tumors, Gynecologic Tumors, or other Hormone Receptor-Positive Solid Tumors NCI-11-C-0061, NCT01273168	Shivaani Kummar 301-435-0517	Janelle Bingham 301-435-2715 jbingham@mail.nih.gov
A Phase I Pharmacokinetic Study of Belinostat for Solid Tumors and Lymphomas in Patients With Varying Degrees of Hepatic Dysfunction NCI-11-C-0060, NCT01273155	Shivaani Kummar 301-435-0517	Janelle Bingham 301-435-2715 jbingham@mail.nih.gov
Phase I Study of the HSP-90 Inhibitor, AT13387, in Adults With Refractory Solid Tumors NCI-11-C-0029, NCT01245218	Shivaani Kummar 301-435-0517	Janelle Bingham 301-435-2715 jbingham@mail.nih.gov
A Pharmacokinetic/Pharmacodynamic Study With a Phase I Run-In With a PARP Inhibitor (Olaparib) in Combination With Carboplatin for Refractory or Recurrent Women’s Cancers NCI-11-C-0022, NCT01237067	Elise C. Kohn 301-402-2726	Laura D. Otten 301-451-1228 1-866-611-6310 (Toll Free) ottenl@mail.nih.gov
A Pilot Study of EZN-2968, an Antisense Oligonucleotide Inhibitor of HIF-1alpha, in Adults With Advanced Solid Tumors NCI-10-C-0113, NCT01120288	Shivaani Kummar 301-435-0517	Janelle Bingham 301-435-2715 jbingham@mail.nih.gov
A Phase I Study of Indenoisoquinolines LMP400 and LMP776 in Adults With Relapsed Solid Tumors and Lymphomas NCI-10-C-0056, NCT01051635	Shivaani Kummar 301-435-0517	Janelle Bingham 301-435-2715 jbingham@mail.nih.gov
A Phase I Study of Belinostat in Combination With Cisplatin and Etoposide in Adults With Small Cell Lung Carcinoma and Other Advanced Cancers NCI-09-C-0173, NCT00926640	Susan Bates 301-402-5958	Christine Bryla 301-451-7868 brylacm@mail.nih.gov
A Phase I, Dose-Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Intravenous Dimethane Sulfonate (DMS612, NSC 281612) in Advanced Malignancies NCI-09-C-0111, NCT00923520	Susan Bates 301-402-5958	Christine Bryla 301-451-7868 brylacm@mail.nih.gov
A Phase I Study of Dasatinib in Combination With Bevacizumab in Advanced Solid Tumors NCI-09-C-0019, NCT01445509	Elise C. Kohn 301-402-2726	Laura D. Otten 301-451-1228 1-866-611-6310 (Toll Free) ottenl@mail.nih.gov
Phase 0
A Single-Dose Pilot Study of Radiolabeled Amatuximab (MORAb-009) in Mesothelin Over Expressing Cancers NCI-11-C-0212, NCT01413451	Raffit Hassan 301-451-8742	Yvonne Mallory 301-402-0255 malloryy@mail.nih.gov
A Phase 0 Trial of [111] Indium CHX-A" DTPA Trastuzumab Imaging in Cancer NCI-07-C-0101, NCT00474578	Peter Choyke 301-402-8409	Yolanda McKinney 301-443-6913 ymckinney@mail.nih.gov
No Phase
Prospective Procurement of Solid Tumor Tissue to Identify Novel Therapeutic Targets NCI-12-C-0175, NCT01658917	Udai Kammula 301-435-8606	Carole Webb 301-402-8475 Webbcc@mail.nih.gov
A Natural History Study of Patients Receiving High Dose Rate Brachytherapy NCI-09-C-0100, NCT00924027	Aradhana Kaushal 301-496-5457	Sharon L. Smith 301-496-5457 smiths@mail.nih.gov
A Pilot Study of Markers of Tumor Burden and Radiation Toxicity in the Blood, Urine, and Stool of Patients Receiving Radiotherapy for Gastrointestinal Malignancies NCI-07-C-0111, NCT00452946	Deborah E. Citrin 301-496-5457	Sharon L. Smith 301-496-5457 smiths@mail.nih.gov
Collection of Serum and Tissue Samples From Patients With Biopsy-Proved or Suspected Malignant Disease NCI-97-C-0147, NCT00026884	W. Marston Linehan 301-496-6353

Trial and Protocol Number Colorectal Cancer	Principal Investigator	Referral Contact
Phase I/II
A Phase I/II Study of ISIS 183750 in Combination With Irinotecan in Irinotecan-refractory Colorectal Cancer NCI-12-C-0187 , NCT01675128	Tim F. Greten 301-451-4723	Suzanne Fioravanti 301-594-6544 fioravas@mail.nih.gov

Trial and Protocol Number Lung Cancer	Principal Investigator	Referral Contact
Phase II
Phase II Evaluation of Mithramycin, an Inhibitor of Cancer Stem Cell Signaling, in Patients With Malignancies Involving Lungs, Esophagus, Pleura, or Mediastinum NCI-12-C-0151, NCT01624090	David S. Schrump 301-496-2128	Tricia Kunst 301-451-1233 tricia_kunst@nih.gov
Phase I
Adjuvant Allogeneic Tumor Cell Vaccine With Metronomic Oral Cyclophosphamide and Celecoxib in Patients Undergoing Resection of Sarcomas, Melanomas, Germ Cell Tumors, or Epithelial Malignancies Metastatic to Lungs, Pleura, or Mediastinum NCI-11-C-0111, NCT01313429	David S. Schrump 301-496-2128	Tricia Kunst 301-451-1233 tricia_kunst@nih.gov

Trial and Protocol Number Pediatric Cancers	Principal Investigator	Referral Contact
Phase I/II
Phase I/II Trial of Mithramycin In Children and Adults With Refractory Extracranial Solid Tumors (Phase I) or Ewing Sarcoma and EWS-FLI1 Fusion Transcript NCI-12-C-0135, NCT01610570	Brigitte Widemann 301-496-7387	Pediatric Oncology 301-496-4256 1-877-624-4878 (Toll free)
Phase I
A Phase I Study of XL184 (Cabozantinib, IND# 116059) in Children and Adolescents With Recurrent or Refractory Solid Tumors, Including CNS Tumors NCI-13-C-0042, NCT01709435	Brigitte Widemann 301-496-7387	Pediatric Oncology 301-496-4256 1-877-624-4878 (Toll free)
A Phase I Study of Ridaforolimus in Pediatric Patients With Advanced Solid Tumors NCI-12-C-0138 , NCT01431534	Lee J. Helman 301-496-4257	Pediatric Oncology 301-496-4256 1-877-624-4878 (Toll free)
A Phase I Dose Escalation Study of Sorafenib and Irinotecan Combination Therapy in Pediatric Patients With Relapsed or Refractory Solid Tumors NCI-12-C-0208, NCT01518413	Brigitte Widemann 301-496-7387	Pediatric Oncology 301-496-4256 1-877-624-4878 (Toll free)
A Phase I Study of Monotherapy Dalotuzumab and Ridaforolimus-Dalotuzumab Combination Treatment in Pediatric Patients With Advanced Solid Tumors NCI-12-C-0140, NCT01431547	Lee J. Helman 301-496-4257	Pediatric Oncology 301-496-4256 1-877-624-4878 (Toll free)
A Phase I Study of NK Cell Infusion Following Allogeneic Peripheral Blood Stem Cell Transplantation From Related or Matched Unrelated Donors in Pediatric Patients With Solid Tumors and Leukemias NCI-11-C-0073, NCT01287104	Kristin Baird 301-496-4256	Pediatric Oncology 301-496-4256 1-877-624-4878 (Toll free)
Phase I Study of Temsirolimus in Combination With Irinotecan and Temozolomide in Children, Adolescents, and Young Adults With Relapsed or Refractory Solid Tumors NCI-11-C-0053, NCT01141244	Brigitte Widemann 301-496-7387	Pediatric Oncology 301-496-4256 1-877-624-4878 (Toll free)
Phase I Trial and Pharmacokinetic Study of the Oral Platinum Analog Satraplatin in Children and Young Adults With Refractory Solid Tumors Including Brain Tumors NCI-11-C-0047, NCT01259479	Brigitte Widemann 301-496-7387	Pediatric Oncology 301-496-4256 1-877-624-4878 (Toll free)
Phase I Trial to Evaluate the Safety, Activity and Pharmacokinetics of Marqibo^® (Vincristine Sulfate Liposomes Injection) in Children and Adolescents With Refractory Cancer NCI-10-C-0220, NCT01222780	Alan S. Wayne 301-496-4256	Pediatric Oncology 301-496-4256 1-877-624-4878 (Toll free)
A Phase 1/2 Study of PF-02341066, An Oral Small Molecule Inhibitor of Anaplastic Lymphoma Kinase (ALK) and C-Met, in Children With Relapsed/Refractory Solid Tumors and Anaplastic Large Cell Lymphoma NCI-10-C-0178, NCT01182896	Brigitte Widemann 301-496-7387	Pediatric Oncology 301-496-4256 1-877-624-4878 (Toll free)
A Phase I Study of Ipilimumab (Anti-CTLA-4) in Children, Adolescents, and Young Adults With Treatment Refractory Cancer NCI-08-C-0007, NCT00556881	Melinda Merchant 301-443-7955	Pediatric Oncology 301-496-4256 1-877-624-4878 (Toll free)

For additional studies that may be appropriate for your disease type, please search under Solid Tumor.